Publicacions en què col·labora amb Oscar Briz Sánchez (82)

2024

  1. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

2023

  1. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  2. Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells

    Biomedicine and Pharmacotherapy, Vol. 165

  3. Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma

    Biochemical Pharmacology, Vol. 214

  4. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

  5. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 217

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

  2. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

  3. Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation

    Cells, Vol. 11, Núm. 24

  4. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems

    Seminars in Liver Disease, Vol. 42, Núm. 1, pp. 087-103

2021

  1. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

    Hepatology, Vol. 73, Núm. 1, pp. 186-203

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression

    Hepatology, Vol. 72, Núm. 3, pp. 949-964

  3. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  4. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma

    Cancers, Vol. 12, Núm. 8, pp. 1-29

  5. Role of genetic variations in the hepatic handling of drugs

    International Journal of Molecular Sciences, Vol. 21, Núm. 8

  6. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters

    Biochemical Pharmacology, Vol. 171

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps

    Archives of Toxicology, Vol. 93, Núm. 3, pp. 623-634

  3. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800